Sofosbuvir，Velpatasvir and Voxilaprevir tablets ;Vosevi, 索磷维伏片（沃士韦）

Sofosbuvir tablets are an antiviral drug used to treat chronic hepatitis C. Through the combined action of three ingredients (sofosbuvir, velpatasvir, and voxilaprevir), they directly inhibit the replication of hepatitis C virus. They are suitable for adult patients with specific genotypes (such as types 1-6), can significantly improve the cure rate and shorten the course of treatment, and must be used strictly in accordance with the doctor’s instructions.

Specific efficacy and effects
Antiviral effect 1.
Sofosbuvir: inhibits viral RNA polymerase and blocks the key link of viral replication.
Velpatasvir and voxilaprevir: target viral non-structural proteins (NS5A, NS3/4A protease), interfering with viral assembly and release.
The combination of the three can cover different life cycles of the virus and reduce the risk of drug resistance.
Indications 2.
For adult patients with chronic hepatitis C, especially those infected with genotypes 1-6.
It is suitable for patients without cirrhosis or compensated cirrhosis, and in some cases can be used for decompensated cirrhosis (doctor evaluation is required).
Treatment advantage 3.
High cure rate: Clinical data show that most patients can achieve virological cure (SVR12) after 12 weeks of treatment.
Short course of treatment: Usually it needs to be taken orally once a day for 12 consecutive weeks, with high compliance.
Fewer side effects: Common adverse reactions include headache, fatigue, etc., most of which are mild.
Precautions for use